Eur Rev Med Pharmacol Sci 2018; 22 (20): 6599-6608

DOI: 10.26355/eurrev_201810_16134

Up-regulation of miR-517-5p inhibits ERK/MMP-2 pathway: potential role in preeclampsia

J.-Y. Fu, Y.-P. Xiao, C.-L. Ren, Y.-W. Guo, D.-H. Qu, J.-H. Zhang, Y.-J. Zhu

Affiliated Hospital of Chengde Medical College, Chengde, China. wenbi5276@163.com


OBJECTIVE: To investigate the potential role of miRNA-517-5p in preeclampsia and its underlying mechanism.

MATERIALS AND METHODS: Placenta samples were obtained from 20 women with preeclampsia and 20 women with normal pregnancies. Expression level of miR-517-5p in placenta samples and JAR cells was detected. MiRNA-517-5p mimics or inhibitor was transfected in JAR cells, followed by detection of proliferative and invasive abilities of JAR cells. In addition, the expressions of extracellular regulated protein kinases (ERK), phospho-extracellular regulated protein kinases (p-ERK) and matrix metalloproteinase-2 (MMP-2) in JAR cells were evaluated by Western blot. Meanwhile, the mRNA level of MMP-2 was evaluated by Real-time polymerase chain reaction (PCR). The luciferase assay was applied to identify the target gene of miRNA-517-5p.

RESULTS: Increased level of miR-517-5p was detected in placenta samples of preeclampsia patients compared with normal pregnancies. MiRNA-517-5p could regulate proliferative and invasive abilities of JAR cells. Furthermore, miRNA-517-5p could regulate ERK/MMP-2 pathway in JAR cells, which would contribute to the pathophysiology of preeclampsia. The luciferase assay showed MMP-2 was the target gene of miR-517-5p. Further studies showed that MMP-2 was dysregulated in preeclampsia.

CONCLUSIONS: MiR-517-5p is highly expressed in placenta samples of preeclampsia pregnancies, which could promote proliferative and invasive abilities of JAR cells by inhibiting ERK/MMP-2 pathway.

Free PDF Download

To cite this article

J.-Y. Fu, Y.-P. Xiao, C.-L. Ren, Y.-W. Guo, D.-H. Qu, J.-H. Zhang, Y.-J. Zhu
Up-regulation of miR-517-5p inhibits ERK/MMP-2 pathway: potential role in preeclampsia

Eur Rev Med Pharmacol Sci
Year: 2018
Vol. 22 - N. 20
Pages: 6599-6608
DOI: 10.26355/eurrev_201810_16134